Lupin Limited (LUPIN.NS) stock analysis

In our weekly check, Lupin Limited is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 1, red flags: 4.

About Lupin Limited

Lupin Limited is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in India, listed on NSE as LUPIN.NS.

What our checks show for LUPIN.NS

Red flags

• Analysts expect the net margin to shrink by 3.1 points from today's 18.5%.
• The stock has fallen as much as 74% from a peak. Would you have held through that?
• Recovering from its deepest fall took about 4.2 years.
• Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.

Warning signs

• Analysts expect earnings per share to shrink about 0.8% a year.

Strengths

• Debt is low: 0x equity.
• Operating profit covers interest 16.7 times over.
• The net margin rose by 27.8 points over 5 years, to 18.5%.
• Operating cash flow is 1.3x net profit: the profit arrives as real cash.
• Revenue grew 21.6% a year over the last 3 years.
• Earnings per share grew 134% a year over the last 3 years.

Next earnings report: 2026-11-03

Similar companies

LAURUSLABS.NS · 4523.T · 6446.TW · TORNTPHARM.NS · DIVISLAB.NS · 4507.T

Questions

What grade does Lupin Limited (LUPIN.NS) have?

In our weekly check, Lupin Limited is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 1, red flags: 4. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of LUPIN.NS stock?

This week's biggest flags for Lupin Limited: Margins expected to shrink, Deep past fall, Slow recovery after falls. In total 5 of 25 checks show a warning or a red flag.

What does Lupin Limited do?

Lupin Limited is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in India, listed on NSE as LUPIN.NS.

When does Lupin Limited report earnings next?

The next earnings report is expected on 2026-11-03. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis